11
Feb 2026
Shared brainwave biomarker bridges mouse and human fragile X research
Numerous potential treatments for neurological conditions, including autism spectrum disorders, have worked well in lab mice but then disappointed in humans.
-
Life can be betterWe are developing drug products isolated from plant extracts
with history in traditional medicine. -
Improving healthImproving health and wellbeing of the people
is our ultimate goal at Mercury Pharmaceuticals. -
ENTREPRENEURIAL MINDSETHands-on approach to manage projects with proactivity and flexibility.
Welcome to Mercury Pharmaceuticals
We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
OUR Science
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
- NeuroscienceAmong the global leaders in Neuroscience
- OncologyTreatments for niche cancers.
- Research & Development Building a sustainable R&D pipeline.
- Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
11
Feb 2026
Economic disadvantage linked to tobacco addiction and lower motivation to stop smoking
A new paper in Nicotine and Tobacco Research, published by Oxford University Press, finds that people experiencing more economic disadvantages are more likely to smoke cigarettes, have higher levels of tobacco addiction, and find it harder to quit than those who are most advantaged.
11
Feb 2026
Promising new speech biomarker could enrich antipsychotic clinical trials
Researchers have identified a promising new speech biomarker that could significantly enrich clinical trials by reducing sample size requirements and enhancing statistical outcomes.
11
Feb 2026
Early heart disease risk factors identified in South Asian adults in the U.S.
South Asian adults in the U. S. were more likely to have risk factors for atherosclerotic cardiovascular disease (ASCVD) by age 45 when compared to white, Black, Chinese or Hispanic adults in the same age group, according to a study published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.